(-) -JJ-450

(-) -JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) . It is more effective than (+) -JJ-450 in inhibiting androgen-induced AR activity, while (+) -JJ-450 inhibits AR via a mechanism distinct from Enzalutamide (MDV3100), possibly targeting the ligand-binding domain (LBD) of AR. (-) -JJ-450 inhibits transcriptional activity of both wild-type AR and the mutant ARF876L by suppressing AR nuclear translocation and promoting intranuclear degradation of unbound AR. This compound can be utilized in research focusing on castration-resistant prostate cancer (CRPC) that is resistant to Enzalutamide.